Investigation of a slope discontinuity in a patients' results distribution for D-dimer

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 12, 2012, Pages 2243-2245

  Jackson, Bryon P ^a   McCloskey, Laura J ^a   Stickle, Douglas F ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Assay imprecision; D dimer; Patient based quality control; Simulation; Statistics

Indexed keywords

D DIMER;

HUMAN; LETTER; LUNG EMBOLISM; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SIMULATION; VENOUS THROMBOEMBOLISM;

FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; PROBABILITY;

EID: 84872832576     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0491     Document Type: Letter

References (7)

1. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009;113:2878-87.
2. Rosa A, Cipollone L, Bertazzoni G. Venous thrombosis in emergency department: diagnosis, treatment, and disposition. Eur Rev Med Pharmacol Sci 2012;16(Suppl 1):48-56.
3. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835-46.
4. van Es J, Mos I, Douma R, Erkens P, Durian M, Nizet T, et al. The combination of four different clinical decision rules and an age-adjusted D-dimer cut-off increases the number of patients in whom acute pulmonary embolism can safely be excluded. Thromb Haemost 2012;107:167-71.
5. de Wolf MA, Wittens CH, Kahn SR. Incidence and risk factors of the post-thrombotic syndrome. Phlebology 2012;27(Suppl 1): 85-94.
6. Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol 2012;87(Suppl 1):S63-7.
7. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008;149:481-90, W94.